<DOC>
	<DOCNO>NCT00497653</DOCNO>
	<brief_summary>To determine oral DCI administration woman PCOS increase total DCI content urine blood , , , change accompany ) increase DCI-IPG release blood ( determined bioactivity ) oral glucose challenge ii ) increase whole-body insulin sensitivity .</brief_summary>
	<brief_title>Oral Administration DCI Women With PCOS</brief_title>
	<detailed_description>A total 46 woman study . We study 23 obese 23 non-obese woman . There BMI restriction . Twenty-three woman randomly assign receive DCI ( experimental group ) 23 woman receive placebo ( control group ) . The woman study equivalent follicular phase cycle , document serum progesterone concentration 2 ng/ml . PCOS define use criterion develop 1990 NICHD conference PCOS3 - i.e. , woman oligomenorrhea ( eight few menstrual period annually ) hyperandrogenemia ( elevate serum total free testosterone concentration ) , secondary cause hyperandrogenism ovulatory dysfunction exclude ( see : Entrance Criteria ) . All woman undergo standard oral glucose tolerance test ( OGTT ) screen diabetes mellitus,16 impaired glucose tolerance ( IGT ) exclusion criterion high prevalence IGT population.8,17-19 We intentionally screen woman presence insulin resistance . Women PCOS disorder associate insulin resistance - hypertension21-23 dyslipidemia21-23 - exclude long stable dose medication 6 month .</detailed_description>
	<mesh_term>Polycystic Ovary Syndrome</mesh_term>
	<criteria>( 1 ) Nonobese obese woman PCOS 1840 year age . ( 2 ) oligomenorrhea ( 8 menstrual period annually ) , ( 3 ) biochemical hyperandrogenemia ( elevated total free testosterone ) , ( 4 ) normal thyroid function test serum prolactin , ( 5 ) exclusion 21 hydroxylase deficiency fast 17 hydroxyprogesterone &lt; 200 ng/dl.41 ( 6 ) acceptable health basis interview , medical history , physical examination , laboratory test ( CBC , SMA20 , urinalysis ) . ( 7 ) Signed , witness informed consent . ( 8 ) Ability comply study requirement . ( 1 ) Diabetes mellitus fast glucose OGTT , clinically significant pulmonary , cardiac , renal , hepatic , neurologic , psychiatric , infectious , neoplastic malignant disease ( nonmelanoma skin cancer ) . ( 2 ) Current use oral contraceptive , DepoProvera Norplant.. ( 3 ) Documented suspected recent ( within one year ) history drug abuse alcoholism . ( 4 ) Ingestion investigational drug within two month prior study onset .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>November 2011</verification_date>
</DOC>